Literature DB >> 7735588

Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1.

B Rijcken1, J P Schouten, X Xu, B Rosner, S T Weiss.   

Abstract

An increased level of airway responsiveness has been proposed as a risk factor associated with the onset and prognosis of chronic airway obstruction. To determine this, longitudinal studies are necessary, with measurement of both the level of airway responsiveness and of additional risk factors, such as cigarette smoking, made before measurement of pulmonary function decline. The association of airways responsiveness with decline in FEV1 has been prospectively studied in a random sample of the Dutch population. Longitudinal data from 921 males, providing 2,376 paired observations, and 698 females, providing 1,682 paired observations, were used for analysis. Differences between responders and nonresponders (PC10 < or = 16 mg/ml of histamine) were estimated from linear regression analyses stratified by gender and smoking status, with adjustment for age, residential area, the presence of respiratory symptoms, indicators for each interval, and residuals of FEV1 at the beginning of the interval. Responders had a greater mean yearly decline in FEV1, and the differences between responders and nonresponders were similar for all gender and smoking subgroups. In an overall regression model, subjects with airway hyperresponsiveness had a significantly steeper decline in FEV1, independent of the other variables (males: beta = -12.5 ml/yr, SEM = 3.22, p < 0.001; females: beta = -11.50 ml/yr, SEM = 2.98, p < 0.001). The current analyses conclusively demonstrated that increased airway responsiveness is an independent risk factor for an accelerated decline in FEV1 and, hence, for the development of chronic obstructive lung disease. The mechanisms by which increased airway responsiveness leads to an accelerated decline in FEV, are imperfectly understood and require further study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7735588     DOI: 10.1164/ajrccm.151.5.7735588

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  31 in total

Review 1.  Inhaled steroids for COPD?

Authors:  A E Tattersfield; T W Harrison
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study.

Authors:  M Pelkonen; I L Notkola; H Tukiainen; M Tervahauta; J Tuomilehto; A Nissinen
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  Health effects of passive smoking. 8. Passive smoking and risk of adult asthma and COPD: an update.

Authors:  D B Coultas
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

4.  Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study.

Authors:  H A Thiadens; G H de Bock; F W Dekker; J A Huysman; J C van Houwelingen; M P Springer; D S Postma
Journal:  BMJ       Date:  1998-04-25

5.  Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids.

Authors:  J K Sont; J Han; J M van Krieken; C E Evertse; R Hooijer; L N Willems; P J Sterk
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 6.  Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease.

Authors:  Julio D Antuni; Peter J Barnes
Journal:  Chronic Obstr Pulm Dis       Date:  2016-06-28

7.  Genetic variation in HTR4 and lung function: GWAS follow-up in mouse.

Authors:  John S House; Huiling Li; Laura M DeGraff; Gordon Flake; Darryl C Zeldin; Stephanie J London
Journal:  FASEB J       Date:  2014-10-23       Impact factor: 5.191

Review 8.  Clinical implications of airway hyperresponsiveness in COPD.

Authors:  Nicola Scichilone; Salvatore Battaglia; Alba La Sala; Vincenzo Bellia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

9.  Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.

Authors:  G T Verhoeven; J P J J Hegmans; P G H Mulder; J M Bogaard; H C Hoogsteden; J-B Prins
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

10.  Respiratory syncytial virus and reactive airway disease.

Authors:  Matthew T Lotz; Martin L Moore; R Stokes Peebles
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.